Zymeworks Inc.
General ticker "ZYME" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $1.8B (TTM average)
Zymeworks Inc. follows the US Stock Market performance with the rate: 30.1%.
Estimated limits based on current volatility of 1.7%: low 24.98$, high 25.83$
Factors to consider:
- Total employees count: 264 (-5.7%) as of 2025
- Top business risk factors: Strategic risks and growth management, Acquisition/divestiture risks, Platform development, Regulatory and compliance, Labor/talent shortage/retention
- Price in estimated range
- Earnings for 6 months up through Q2 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [15.40$, 31.94$]
- 2026-12-31 to 2027-12-31 estimated range: [12.19$, 26.42$]
Financial Metrics affecting the ZYME estimates:
- Positive: with PPE of -24.8 at the end of fiscal year the price was neutral
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -1.63 <= 2.37
- Negative: negative Net income
- Negative: Inventory ratio change, % of 22.88 > 4.02
- Negative: negative Industry operating income (median)
- Negative: Industry earnings per price (median), % of -15.99 <= 0
Short-term ZYME quotes
Long-term ZYME plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $76.01MM | $76.30MM | $105.97MM |
| Operating Expenses | $214.06MM | $213.41MM | $198.50MM |
| Operating Income | $-138.05MM | $-137.11MM | $-92.53MM |
| Non-Operating Income | $18.81MM | $20.50MM | $12.78MM |
| R&D Expense | $143.62MM | $134.62MM | $137.00MM |
| Income(Loss) | $-119.24MM | $-116.61MM | $-79.75MM |
| Taxes | $-0.57MM | $6.08MM | $1.38MM |
| Net Income(Loss)* | $-118.67MM | $-122.69MM | $-81.13MM |
| Stockholders Equity | $464.81MM | $338.77MM | $268.50MM |
| Assets | $580.88MM | $463.09MM | $346.53MM |
| Operating Cash Flow | $-118.32MM | $-110.06MM | $-33.01MM |
| Capital expenditure | $4.08MM | $3.07MM | $1.52MM |
| Investing Cash Flow | $-207.25MM | $38.76MM | $26.66MM |
| Financing Cash Flow | $81.87MM | $-20.44MM | $-18.56MM |
| Earnings Per Share** | $-1.72 | $-1.62 | $-1.08 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.